$190.11
0.55%
Nasdaq, Jan 02, 10:00 pm CET

Ligand Pharmaceuticals Incorporated Stock price

$190.11
-4.99 2.56% 1M
+76.45 67.26% 6M
+1.04 0.55% YTD
+81.69 75.35% 1Y
+123.31 184.60% 3Y
+128.47 208.43% 5Y
+127.62 204.22% 10Y
+159.52 521.50% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+1.04 0.55%

Key metrics

Basic
Market capitalization
$3.7b
Enterprise Value
$3.5b
Net debt
positive
Cash
$664.5m
Shares outstanding
19.7m
Valuation (TTM | estimate)
P/E
80.9 | 25.5
P/S
14.9 | 14.6
EV/Sales
14.0 | 13.8
EV/FCF
114.5
P/B
3.9
Financial Health
Equity Ratio
88.2%
Return on Equity
-0.5%
ROCE
2.0%
ROIC
2.8%
Debt/Equity
0.5
Financials (TTM | estimate)
Revenue
$251.2m | $255.5m
EBITDA
$61.7m | $108.8m
EBIT
$28.8m | $50.2m
Net Income
$48.6m | $146.6m
Free Cash Flow
$30.8m
Growth (TTM | estimate)
Revenue
64.8% | 52.9%
EBITDA
21.9% | 94.4%
EBIT
64.0% | 118.1%
Net Income
7.9% | 3,738.7%
Free Cash Flow
24.1%
Margin (TTM | estimate)
Gross
94.3%
EBITDA
24.6% | 42.6%
EBIT
11.5%
Net
19.3% | 57.4%
Free Cash Flow
12.2%
More
EPS
$2.4
FCF per Share
$1.6
Short interest
6.7%
Employees
68
Rev per Employee
$2.5m
Show more

Is Ligand Pharmaceuticals Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Ligand Pharmaceuticals Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:

Buy
92%
Hold
8%

Financial data from Ligand Pharmaceuticals Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
251 251
65% 65%
100%
- Direct Costs 14 14
46% 46%
6%
237 237
66% 66%
94%
- Selling and Administrative Expenses 93 93
34% 34%
37%
- Research and Development Expense 82 82
265% 265%
33%
62 62
22% 22%
25%
- Depreciation and Amortization 33 33
1% 1%
13%
EBIT (Operating Income) EBIT 29 29
64% 64%
11%
Net Profit 49 49
8% 8%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Ligand Pharmaceuticals Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ligand Pharmaceuticals Incorporated Stock News

marktEINBLICKE
19 days ago
Auslaufende Patente, lockere Fed-Politik und Boom bei Adipositas: Warum Biotech-Übernahmen wieder anziehen und Anleger neue Chancen wittern.
Neutral
Seeking Alpha
25 days ago
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
Neutral
GlobeNewsWire
26 days ago
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per diluted share of $8.00 to $9.002 Increases 5-year royalty receipt outlook driven by Filspari, Ohtuvayre, and Zelsuvmi; expects to meet or exceed 23% compound ...
More Ligand Pharmaceuticals Incorporated News

Company Profile

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Head office United States
CEO Todd Davis
Employees 68
Founded 1987
Website www.ligand.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today